Key result
The Omron HEM 742 oscillometric device demonstrated good reproducibility and agreement for detecting resting heart rate in breast cancer survivors compared with a Polar RS800 CX cardiac monitor.
Why the study?
Does the Omron HEM 742 oscillometric device accurately measure resting heart rate compared to a validated cardiac monitor in breast cancer survivors?
Cross-Sectional (n=85)
Does the Omron HEM 742 oscillometric device accurately measure resting heart rate compared to a validated cardiac monitor in breast cancer survivors?
The Omron HEM 742 oscillometric device provides reproducible and accurate resting heart rate measurements in breast cancer survivors compared to a validated heart rate monitor.
Supports RHR monitoring with this device in survivors; leaves open broader validation before routine use.
OBJECTIVE: The aim of this study was to verify the reproducibility of an oscillometric device in the measurement of resting heart rate (RHR) in breast cancer survivors. METHODS: This study included 85 breast cancer survivors with a mean age of 58.87±10.03 years. For the RHR evaluation, the equipment used was the Omron HEM 742, electronic and digital arm device, for measurement of blood pressure and heart rate (HR), with automatic cuff inflation and deflation. At the same time as the oscillometric measurement, HR was measured by the HR monitor Polar RS800 CX, which has been validated previously for HR uptake. The HR value obtained by the cardiofrequency meter was registered at the same time that the Omron device measured blood pressure and HR values. RESULTS: It was observed that the RHR values were very close in both devices and that the correlation values and intraclass correlation coefficient were high. These results were replicated when the female breast cancer survivors were stratified by age group. The agreement values presented by the Bland-Altman analysis showed good values; both for the entire sample and stratified by age, few cases were outside beyond 95% confidence interval range. CONCLUSION: The present study showed that the oscillometric device used presented good values of reproducibility in the detection of RHR values in breast cancer survivors compared with a cardiac monitor.
No takes yet. Share an insight, caveat, or question.
Palma et al. (2017) conducted a cross-sectional in Breast cancer (n=85). Omron HEM 742 oscillometric device vs. Polar RS800 CX heart rate monitor was evaluated on Reproducibility and agreement of resting heart rate measurement. The Omron HEM 742 oscillometric device demonstrated good reproducibility and agreement for detecting resting heart rate in breast cancer survivors compared with a Polar RS800 CX cardiac monitor.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: